Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Levothyroxine Sodium,Inapplicable
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Jerome Stevens Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Jerome Announces Acquisition of Thyquidity (Levothyroxine Sodium Oral Solution)
Details : Jerome acquires Thyquidity (levothyroxine sodium) from Azurity. It is indicated for the treatment of Hypothyroidism.
Product Name : Thyquidity
Product Type : Hormone
Upfront Cash : Undisclosed
April 01, 2025
Lead Product(s) : Levothyroxine Sodium,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Jerome Stevens Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Levothyroxine Sodium,Liothyronine Sodium
Therapeutic Area : Endocrinology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novel Approaches to the Treatment of Hypothyroidism
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 12, 2024
Lead Product(s) : Levothyroxine Sodium,Liothyronine Sodium
Therapeutic Area : Endocrinology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levothyroxine Sodium,Enlicitide Decanoate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Celerion
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2024
Lead Product(s) : Levothyroxine Sodium,Enlicitide Decanoate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Celerion
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levothyroxine Sodium,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Levothyroxine-sodium Bioequivalence Trial With Oral Single Dose Administration
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 09, 2024
Lead Product(s) : Levothyroxine Sodium,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levothyroxine Sodium,Inapplicable
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Xeris Biopharma Reports Positive Phase 2 Data for Once-Weekly Levothyroxine
Details : XP-8121 (levothyroxine) is a Investigational hormome, administered via Subcutaneous injection for the treatment of acquired thyroid disease.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : Levothyroxine Sodium,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levothyroxine Sodium,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : University of Sharjah
Deal Size : Inapplicable
Deal Type : Inapplicable
Impact of Increasing Levothyroxine Dose in Ramadan for UAE Patients With Hypothyroidism
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 18, 2023
Lead Product(s) : Levothyroxine Sodium,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : University of Sharjah
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levothyroxine Sodium,Inapplicable
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Mark Cuban Cost Plus Drug Company
Deal Size : Undisclosed
Deal Type : Agreement
IBSA Pharma and Mark Cuban Cost Plus Drug Company Team Up to Make Tirosint More Affordable
Details : Tirosint capsules is the leading branded gel capsule formulation of levothyroxine sodium in the US. It is formulated without excipients that can cause tolerability and drug absorption problems commonly observed with traditional levothyroxine tablet thera...
Product Name : Tirosint
Product Type : Hormone
Upfront Cash : Undisclosed
July 03, 2023
Lead Product(s) : Levothyroxine Sodium,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Mark Cuban Cost Plus Drug Company
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Levothyroxine Sodium,Inapplicable
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XP-8121 (levothyroxine) is a Investigational Subcutaneous injection thus indicated for acquired thyroid disease (primary hypothyroidism), in cases of decreased secretion of TSH from the anterior pituitary gland (secondary hypothyroidism),
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
June 21, 2023
Lead Product(s) : Levothyroxine Sodium,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levothyroxine Sodium,Inapplicable
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
April 21, 2023
Lead Product(s) : Levothyroxine Sodium,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levothyroxine Sodium,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Receives Final Approval from the USFDA for Levothyroxine Sodium for Injection
Details : Levothyroxine sodium is a medicine used to treat an underactive thyroid gland (hypothyroidism). The thyroid gland makes thyroid hormones which help to control energy levels and growth. Levothyroxine is taken to replace the missing thyroid hormone thyroxi...
Product Name : Levothyroxine Sodium-Generic
Product Type : Hormone
Upfront Cash : Inapplicable
March 28, 2023
Lead Product(s) : Levothyroxine Sodium,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable